Daniel Hilton, MD
Internal Medicine · Huntington Beach, CANPI 1093811358
Payments from drug & device makers
Across 31 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$140
- AbbVie$59
- CMP Pharma, Inc.$48
- Abbott$48
- Teva Pharmaceuticals USA, Inc.$42
- Kowa Pharmaceuticals America, Inc.$40
- plus $311 from 15 others
What the payments were for
- Food & beverage$688100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 5 | $140 |
| AbbVie | 2 | $59 |
| CMP Pharma, Inc. | 2 | $48 |
| Abbott | 2 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 2 | $40 |
| Boehringer Ingelheim | 1 | $26 |
| Straumann USA LLC | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| X4 Pharmaceuticals, Inc. | 1 | $24 |
| Urovant Sciences Inc | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 2 | $23 |
| Stryker | 1 | $22 |
| Radius Health, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
How this compares
$688 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 14 | $119,881 |
| EliquisApixaban | 257 | $112,591 |
| CreonLipase/Protease/Amylase | 43 | $39,799 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $28,959 |
| SantylCollagenase Clostridium Hist. | 32 | $21,802 |
| JardianceEmpagliflozin | 48 | $21,711 |
| LinzessLinaclotide | 38 | $19,561 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 100 | $19,125 |
| XareltoRivaroxaban | 26 | $18,577 |
| JanuviaSitagliptin Phosphate | 20 | $17,927 |
| Budesonide | 80 | $17,801 |
| OzempicSemaglutide | 16 | $14,966 |
| MyrbetriqMirabegron | 31 | $13,611 |
| MounjaroTirzepatide | 11 | $11,827 |
| RestasisCyclosporine | 18 | $11,214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Restasis, Lumigan | $59 | $75,660110 claims |
| Boehringer IngelheimJardiance, Tradjenta | $26 | $25,65663 claims |
| Johnson & JohnsonXarelto | $140 | $18,57726 claims |
| Lilly USA, LLCMounjaro, Humalog | $15 | $16,39272 claims |
| Novo NordiskOzempic | $17 | $14,96616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Huntington Beach
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.